Key Challenges and Opportunities Associated with the Use of in Vitro Models to Detect Human Dili: Integrated Risk Assessment and Mitigation Plans

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Atienzar, Franck A ^a   Blomme, Eric A ^b   Chen, Minjun ^c   Hewitt, Philip ^d   Kenna, J Gerry ^e   Labbe, Gilles ^f   Moulin, Frederic ^g   Pognan, Francois ^h   Roth, Adrian B ⁱ   Suter Dick, Laura ^j   Ukairo, Okechukwu ^k   Weaver, Richard J ^l   Will, Yvonne ^m   Dambach, Donna M ⁿ  

^a UCB PHARMA   (Belgium)

^b ABBVIE INC   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d MERCK KGAA   (Germany)

^e Drug Safety Consultant   (United Kingdom)

^f SANOFI   (France)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^k IPSEN   (France)

^l IRIS Institut de Recherches Internationales Servier   (France)

^m PFIZER INC   (United States)

ⁿ GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIALURIDINE;

CLINICAL OUTCOME; CLINICAL STUDY; DISEASE CLASSIFICATION; DRUG INDUSTRY; GENOTOXICITY; HEALTH CARE PRACTICE; HUMAN; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PRECLINICAL STUDY; REVIEW; RISK ASSESSMENT; STANDARDIZATION; TOXIC HEPATITIS;

EID: 84988731993     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/9737920     Document Type: Review

References (169)

1. J. L. Stevens and T. K. Baker, "The future of drug safety testing: expanding the view and narrowing the focus," Drug Discovery Today, vol. 14, no. 3-4, pp. 162-167, 2009
2. J. S. MacDonald and R. T. Robertson, "Toxicity testing in the 21st century: a viewfromthe pharmaceutical industry," Toxicological Sciences, vol. 110, no. 1, pp. 40-46, 2009
3. J. J. Van Tonder, V. Steenkamp, and M. Gulumian, "Pre-clinical assessment of the potential intrinsic hepatotoxicity of candidate drugs," in New Insights into Toxicity and Drug Testing, S. Gowder, Ed. , vol. 28, chapter 1, pp. 3-28, InTech, 2013
4. G. Ostapowicz, R. J. Fontana, F. V. Schioødt et al. , "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States," Annals of Internal Medicine, vol. 137, no. 12, pp. 947-954, 2002
5. R. J. Andrade, R. Camargo, M. I. Lucena, and R. González-Grande, "Causality assessment in drug-induced hepatotoxicity," Expert Opinion on Drug Safety, vol. 3, no. 4, pp. 329-344, 2004
6. L. N. Bell and N. Chalasani, "Epidemiology of idiosyncratic drug-induced liver injury," Seminars in LiverDisease, vol. 29,no. 4, pp. 337-347, 2009
7. H. J. Zimmerman, "Drug-induced liver disease," Clinics in Liver Disease, vol. 4, no. 1, pp. 73-96, 2000
8. N. Kaplowitz, "Idiosyncratic drug hepatotoxicity," Nature Reviews Drug Discovery, vol. 4, no. 6, pp. 489-499, 2005
9. S. Russmann, G. A. Kullak-Ublick, and I. Grattagliano, "Current concepts of mechanisms in drug-induced hepatotoxicity," Current Medicinal Chemistry, vol. 16, no. 23, pp. 3041-3053, 2009
10. M. L. Greer, J. Barber, J. Eakins, and J. G. Kenna, "Cell based approaches for evaluation of drug-induced liver injury," Toxicology, vol. 268, no. 3, pp. 125-131, 2010
11. J. Li and P. J. Uetrecht, "Danger hypothesis applied to idiosyncratic drug reactions," in Adverse Drug Reactions, Handbook of Experimental Pharmacology, J. Uetrecht, Ed. , pp. 493-509, Springer, NewYork, NY,USA, 2010
12. M. D. Leise, J. J. Poterucha, and J. A. Talwalkar, "Drug-induced liver injury," Mayo Clinic Proceedings, vol. 89, no. 1, pp. 95-106, 2014
13. A. P. Li, "An integrated, multidisciplinary approach for drug safety assessment," Drug Discovery Today, vol. 9, no. 16, pp. 687-693, 2004
14. R. G. Ulrich, "Idiosyncratic toxicity: a convergence of risk factors," Annual Review of Medicine, vol. 58, pp. 17-34, 2007
15. W. M. Lee, "Drug-induced hepatotoxicity," The New England Journal of Medicine, vol. 349, no. 5, pp. 474-485, 2003
16. A. Guillouzo and C. Guguen-Guillouzo, "Evolving concepts in liver tissue modeling and implications for in vitro toxicology," Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 10, pp. 1279-1294, 2008
17. U. A. Boelsterli and P. L. K. Lim, "Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity" Toxicology and Applied Pharmacology, vol. 220, no. 1, pp. 92-107, 2007
18. J. A. Dykens and Y. Will, "The significance of mitochondrial toxicity testing in drug development," Drug Discovery Today, vol. 12, no. 17-18, pp. 777-785, 2007
19. R. E. Morgan, M. Trauner, C. J. van Staden et al. , "Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development," Toxicological Sciences, vol. 118, no. 2, pp. 485-500, 2010
20. B. K. Park, A. Boobis, S. Clarke et al. , "Managing the challenge of chemically reactive metabolites in drug development," Nature Reviews Drug Discovery, vol. 10, no. 4, pp. 292-306, 2011
21. P. Godoy,N. J. Hewitt,U. Albrecht et al. , "Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME," Archives of Toxicology, vol. 87, no. 8, pp. 1315-1530, 2013
22. C. Lammert, E. Bjornsson, A. Niklasson, and N. Chalasani, "Oralmedications with significant hepatic metabolism at higher risk for hepatic adverse events," Hepatology, vol. 51, no. 2, pp. 615-620, 2010
23. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, and N. Chalasani, "Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals," Hepatology, vol. 47, no. 6, pp. 2003-2009, 2008
24. M. I. Lucena, R. J. Andrade, N. Kaplowitz et al. , "Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex," Hepatology, vol. 49, no. 6, pp. 2001-2009, 2009
25. N. Chalasani and E. Björnsson, "Risk factors for idiosyncratic drug-induced liver injury," Gastroenterology, vol. 138, no. 7, pp. 2246-2259, 2010
26. S. David and J. P. Hamilton, "Drug-induced liver injury," Gastroenterology and Hepatology Reviews, vol. 6, pp. 73-80, 2010
27. H. Olson, G. Betton, J. Stritar, and D. Robinson, "The predictivity of the toxicity of pharmaceuticals in humans fromanimal data-an interim assessment," Toxicology Letters, vol. 102-103, pp. 535-538, 1998
28. J. Lu, S. Einhorn, L. Venkatarangan et al. , "Morphological and functional characterization and assessment of iPSC-derived hepatocytes for in vitro toxicity testing," Toxicological Sciences, vol. 147, no. 1, Article IDkfv117, pp. 39-54, 2015
29. R. Kostadinova, F. Boess, D. Applegate et al. , "A long-termthree dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity," Toxicology and Applied Pharmacology, vol. 268, no. 1, pp. 1-16, 2013
30. S. Messner, I. Agarkova, W. Moritz, and J. M. Kelm, "Multicell type human liver microtissues for hepatotoxicity testing," Archives of Toxicology, vol. 87, no. 1, pp. 209-213, 2013
31. I. Maschmeyer, A. K. Lorenz, K. Schimek et al. , "A fourorgan-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents," Lab on a Chip, vol. 15, no. 12, pp. 2688-2699, 2015
32. L. A. Vernetti, N. Senutovitch, R. Boltz et al. , "A human liver microphysiology platform for investigating physiology, drug safety, and diseasemodels," Experimental Biology and Medicine, vol. 241, no. 1, pp. 101-114, 2016
33. A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo, "The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics," Chemico-Biological Interactions, vol. 168, no. 1, pp. 66-73, 2007
34. M. Le Vee, G. Noel, E. Jouan, B. Stieger, and O. Fardel, "Polarized expression of drug transporters in differentiated human hepatomaHepaRG cells," Toxicology in Vitro, vol. 27, no. 6, pp. 1979-1986, 2013
35. I. Itzhaki, L. Maizels, I. Huber et al. , "Modelling the long QT syndrome with induced pluripotent stem cells," Nature, vol. 471, no. 7337, pp. 225-229, 2011
36. F. Lan, A. S. Lee, P. Liang et al. , "Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells," Cell Stem Cell, vol. 12, no. 1, pp. 101-113, 2013
37. N. Sun, M. Yazawa, J. Liu et al. , "Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy," Science Translational Medicine, vol. 4, no. 130, Article ID 130ra47, 2012
38. R. C. Saumarez, L. Chojnowska, R. Derksen et al. , "Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation," Circulation, vol. 107, no. 20, pp. 2595-2600, 2003
39. P. Liang, F. Lan, A. S. Lee et al. , "Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity," Circulation, vol. 127, no. 16, pp. 1677-1691, 2013
40. F. C. Richardson, J. A. Engelhardt, and R. R. Bowsher, "Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 25, pp. 12003-12007, 1994
41. P. Honkoop, H. R. Scholte, R. A. De Man, and S. W. Schalm, "Mitochondrial injury. Lessons from the fialuridine trial," Drug Safety, vol. 17, no. 1, pp. 1-7, 1997
42. R. McKenzie, M. W. Fried, R. Sallie et al. , "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B," The New England Journal of Medicine, vol. 333, no. 17, pp. 1099-1105, 1995
43. J. Lebron, L. Liu, S. Kulkarni et al. , "Differential effects of FIAU, FIRU and DDC on functional and DNA content endpoints in HepatoPac- and Huh-7 cells," in Proceedings of the 54th Annual Meeting of the Society of Toxicology, abstract 621, San Diego, Calif, USA, March 2015
44. H. Olson, G. Betton, D. Robinson et al. , "Concordance of the toxicity of pharmaceuticals in humans and in animals," Regulatory Toxicology and Pharmacology, vol. 32, no. 1, pp. 56-67, 2000
45. J. W. Benbow, J. Aubrecht, M. J. Banker, D. Nettleton, and M. D. Aleo, "Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies," Toxicology Letters, vol. 197, no. 3, pp. 175-182, 2010
46. N. Greene, M. D. Aleo, S. Louise-May, D. A. Price, and Y. Will, "Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies," Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 17, pp. 5308-5312, 2010
47. F. Shah, L. Leung, H. A. Barton et al. , "Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays," Toxicological Sciences, vol. 147, no. 2, Article ID kfv152, pp. 500-514, 2015
48. R. A. Thompson, E. M. Isin, Y. Li et al. , "In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs," Chemical Research in Toxicology, vol. 25, no. 8, pp. 1616-1632, 2012
49. M. Chen, C.-W. Tung, Q. Shi et al. , "A testing strategy to predict risk for drug-induced liver injury in humans using highcontent screen assays and the 'rule-of-two' model," Archives of Toxicology, vol. 88, no. 7, pp. 1439-1449, 2014
50. J. R. W. Masters, "Human cancer cell lines: fact and fantasy," Nature ReviewsMolecular Cell Biology, vol. 1, no. 3, pp. 233-236, 2000
51. N. Wong, P. Lai, E. Pang, T. Wai-Tong Leung, J. Wan-Yee Lau, and P. James Johnson, "A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping," Hepatology, vol. 32, no. 5, pp. 1060-1068, 2000
52. A. Dove, "The art of culture: developing cell lines," Science, vol. 346, no. 6212, pp. 1013-1015, 2014
53. Z. Kmiec, "Cooperation of liver cells in health and disease," Advances in Anatomy, Embryology and Cell Biology, vol. 161, no. 3-13, pp. 1-151, 2001
54. R. A. Roberts, P. E. Ganey, C. Ju, L. M. Kamendulis, I. Rusyn, and J. E. Klaunig, "Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis," Toxicological Sciences, vol. 96, no. 1, pp. 2-15, 2007
55. D. Germano, M. Uteng, F. Pognan, S.-D. Chibout, and A. Wolf, "Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment," Toxicology in Vitro, vol. 30, no. 1, pp. 79-94, 2014
56. B. Swift, N. D. Pfeifer, and K. L. R. Brouwer, "Sandwichcultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity," Drug Metabolism Reviews, vol. 42, no. 3, pp. 446-471, 2010
57. N. I. Kramer, E. Di Consiglio, B. J. Blaauboer, and E. Testai, "Biokinetics in repeated-dosing in vitro drug toxicity studies," Toxicology in Vitro, vol. 30, no. 1, pp. 217-224, 2015
58. I. Martinez, G. I. Nedredal, C. I. Øie et al. , "The influence of oxygen tension on the structure and function of isolated liver sinusoidal endothelial cells," Comparative Hepatology, vol. 7, article 4, 2008
59. M. Balls, "In vitromethods in regulatory toxicology: the crucial significance of validation," in Toxicology in Transition, G. H. Degen, J. P. Seiler, and P. Bentley, Eds. , vol. 17 of Archives of Toxicology, pp. 155-162, 1995
60. J. J. Xu, P. V. Henstock, M. C. Dunn, A. R. Smith, J. R. Chabot, and D. de Graaf, "Cellular imaging predictions of clinical druginduced liver injury," Toxicological Sciences, vol. 105, no. 1, pp. 97-105, 2008
61. P. J. O'Brien, W. Irwin, D. Diaz et al. , "High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening," Archives of Toxicology, vol. 80, no. 9, pp. 580-604, 2006
62. F. A. Atienzar, E. I. Novik,H. H. Gerets et al. , "Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans," Toxicology and Applied Pharmacology, vol. 275, no. 1, pp. 44-61, 2014
63. F. Gustafsson, A. J. Foster, S. Sarda, M. H. Bridgland-Taylor, and J. G. Kenna, "A correlation between the in vitro drug toxicity of drugs to cell lines that express human p450s and their propensity to cause liver injury in humans," Toxicological Sciences, vol. 137, no. 1, pp. 189-211, 2014
64. M. Chen, H. Hong, H. Fang et al. , "Quantitative structureactivity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs," Toxicological Sciences, vol. 136, no. 1, pp. 242-249, 2013
65. M. Chen, A. Suzuki, S. Thakkar, K. Yu, C. Hu, and W. Tong, "DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans," Drug Discovery Today, vol. 21, no. 4, pp. 648-653, 2016
66. M. Biour, C. Ben Salem, O. Chazouillères, J.-D. Grangé, L. Serfaty, and R. Poupon, "Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs," Gastroenterologie Clinique et Biologique, vol. 28, no. 8-9, pp. 720-759, 2004
67. D. Thompson, "Lack of adequate classification of hepatotoxicants hinders development of predictive in vitro screening assays," Annual Meeting Abstract Supplement, Society of Toxicology, Abstract no. 2017, 2016
68. M. Chen, V. Vijay, Q. Shi, Z. Liu, H. Fang, and W. Tong, "FDAapproved drug labeling for the study of drug-induced liver injury," Drug Discovery Today, vol. 16, no. 15-16, pp. 697-703, 2011
69. H. H. J. Gerets, K. Tilmant, B. Gerin et al. , "Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins," Cell Biology and Toxicology, vol. 28, no. 2, pp. 69-87, 2012
70. L. Tolosa, S. Pinto, M. T. Donato et al. , "Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs," Toxicological Sciences, vol. 127, no. 1, pp. 187-198, 2012
71. S. R. Khetani, C. Kanchagar, O. Ukairo et al. , "Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans," Toxicological Sciences, vol. 132, no. 1, pp. 107-117, 2013
72. H. H. J. Gerets, E. Hanon, M. Cornet et al. , "Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach," Toxicology in Vitro, vol. 23, no. 2, pp. 319-332, 2009
73. S. K. Bopp and T. Lettieri, "Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line," BMC Pharmacology, vol. 8, article 8, 2008
74. A. Ullrich, C. Berg, J. G. Hengstler, and D. Runge, "Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion," Altex, vol. 24, no. 1, pp. 35-40, 2007
75. W. G. E. J. Schoonen, W. M. A. Westerink, J. A. D. M. De Roos, and E. Débiton, "Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake," Toxicology in Vitro, vol. 19, no. 4, pp. 505-516, 2005
76. S. Nadanaciva, P. Rana, G. C. Beeson et al. , "Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform," Journal of Bioenergetics and Biomembranes, vol. 44, no. 4, pp. 421-437, 2012
77. S. Nadanaciva, M. D. Aleo, C. J. Strock, D. B. Stedman, H. Wang, and Y. Will, "Toxicity assessments of nonsteroidal antiinflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes," Toxicology and Applied Pharmacology, vol. 272, no. 2, pp. 272-280, 2013
78. J. Eakins, C. Bauch, H. Woodhouse et al. , "A combined in vitro approach to improve the prediction ofmitochondrial toxicants," Toxicology in Vitro, vol. 34, pp. 161-170, 2016
79. K. Tilmant, H. H. J. Gerets, S. Dhalluin et al. , "Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis," Toxicology in Vitro, vol. 25, no. 7, pp. 1414-1424, 2011
80. M. Persson, A. F. Løye, M. Jacquet et al. , "High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity," Basic and Clinical Pharmacology and Toxicology, vol. 115, no. 1, pp. 18-23, 2014
81. M. Uteng, D. Germano, K. K. Balavenkatraman, F. Pognan, and A. Wolf, "High content imaging approaches for in vitro toxicology," in In Vitro Toxicology Systems, A. Bal-Price and P. Jennings, Eds. , Methods in Pharmacology and Toxicology, pp. 377-397, 2014
82. M. Porceddu, N. Buron, C. Roussel, G. Labbe, B. Fromenty, and A. Borgne-Sanchez, "Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria," Toxicological Sciences, vol. 129, no. 2, pp. 332-345, 2012
83. S. Schadt, S. Simon, S. Kustermann et al. , "Minimizing DILI risk in drug discovery-a screening tool for drug candidates," Toxicology in Vitro, vol. 30, no. 1, pp. 429-437, 2015
84. O. Ukairo,C. Kanchagar,A. Moore et al. , "Long-termstability of primary rat hepatocytes in micropatterned cocultures," Journal of Biochemical and Molecular Toxicology, vol. 27, no. 3, pp. 204-212, 2013
85. L. D. Marroquin, J. Hynes, J. A. Dykens, J. D. Jamieson, and Y. Will, "Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of hepG2 cells to mitochondrial toxicants," Toxicological Sciences, vol. 97, no. 2, pp. 539-547, 2007
86. V. M. Gohil, S. A. Sheth, R. Nilsson et al. , "Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis," Nature Biotechnology, vol. 28, no. 3, pp. 249-255, 2010
87. C. Yuan, J. Gao, J. Guo et al. , "Dimethyl sulfoxide damages mitochondrial integrity and membrane potential in cultured astrocytes," PLoS ONE, vol. 9, no. 9,Article ID e107447, 2014
88. C. Sanmartín-Suárez, R. Soto-Otero, I. Sánchez-Sellero, and E. Méndez-Alvarez, "Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants," Journal of Pharmacological and Toxicological Methods, vol. 63, no. 2, pp. 209-215, 2011
89. J. Jiang, J. E. J. Wolters, S. G. van Breda, J. C. Kleinjans, and T. M. de Kok, "Development of novel tools for the in vitro investigation of drug-induced liver injury," Expert Opinion on Drug Metabolism & Toxicology, vol. 11, no. 10, pp. 1523-1537, 2015
90. E. Curcio, S. Salerno, G. Barbieri, L. De Bartolo, E. Drioli, and A. Bader, "Mass transfer and metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane system," Biomaterials, vol. 28, no. 36, pp. 5487-5497, 2007
91. R. Glicklis, J. C. Merchuk, and S. Cohen, "Modeling mass transfer in hepatocyte spheroids via cell viability, spheroid size, and hepatocellular functions," Biotechnology and Bioengineering, vol. 86, no. 6, pp. 672-680, 2004
92. T. Anada, J. Fukuda, Y. Sai, and O. Suzuki, "An oxygenpermeable spheroid culture system for the prevention of central hypoxia and necrosis of spheroids," Biomaterials, vol. 33, pp. 8430-8441, 2012
93. A. Benesic and A. L. Gerbes, "Drug-induced liver injury and individual cell models," Digestive Diseases, vol. 33, no. 4, pp. 486-491, 2015
94. S. B. Leite, T. Roosens, A. El Taghdouini et al. , "Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro," Biomaterials, vol. 78, pp. 1-10, 2016
95. A. Roth and T. Singer, "The application of 3D cell models to support drug safety assessment: opportunities & challenges," Advanced Drug Delivery Reviews, vol. 69-70, pp. 179-189, 2014
96. S. O. Mueller,A. Guillouzo, P. G. Hewitt, and L. Richert, "Drug biokinetic and toxicity assessments in rat and human primary hepatocytes and HepaRG cells within the EU-funded Predict-IV project," Toxicology in Vitro, vol. 30, no. 1, pp. 19-26, 2015
97. C. Goldring, A. Norris, N. Kitteringham et al. , "Mechanismbased markers of drug-induced liver injury to improve the physiological relevance and predictivity of in vitro models," Applied in Vitro Toxicology, vol. 1, no. 3, pp. 175-186, 2015
98. S. Takai, S. Oda, K. Tsuneyama, T. Fukami, M. Nakajima, and T. Yokoi, "Establishment of a mouse model for amiodaroneinduced liver injury and analyses of its hepatotoxicmechanism," Journal of Applied Toxicology, vol. 36, no. 1, pp. 35-47, 2016
99. I. G. Metushi, P. Cai, D. Dervovic et al. , "Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset," Journal of Immunotoxicology, vol. 12, no. 3, pp. 247-260, 2015
100. M. R. McGill, H.-M. Yan, A. Ramachandran, G. J. Murray, D. E. Rollins, and H. Jaeschke, "HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity," Hepatology, vol. 53, no. 3, pp. 974-982, 2011
101. E. Patel, L. M. Cole, R. Bradshaw et al. , "MALDI-MS imaging for the study of tissue pharmacodynamics and toxicodynamics," Bioanalysis, vol. 7, no. 1, pp. 91-101, 2015
102. G. Levy, D. Bomze, S. Heinz et al. , "Long-term culture and expansion of primary human hepatocytes," Nature Biotechnology, vol. 33, no. 12, pp. 1264-1271, 2015
103. D. Mueller, L. Krämer, E. Hoffmann, S. Klein, and F. Noor, "3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies," Toxicology in Vitro, vol. 28, no. 1, pp. 104-112, 2014
104. M. Hadi, I. M. Westra, V. Starokozhko, S. Dragovic, M. T. Merema, and G. M. M. Groothuis, "Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury," Chemical Research in Toxicology, vol. 26, no. 5, pp. 710-720, 2013
105. E. C. G. U. t. I. M. I. Mip Dili, "Mechanism-Based Integrated Prediction of Drug-Induced Liver Injury," European, Patent no. Grant Agreement number 115336
106. R. L. C. Sison-Young,D. Mitsa, R. E. Jenkins et al. , "Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication," Toxicological Sciences, vol. 147, no. 2, pp. 412-424, 2015
107. D. B. Njoku, "Drug-induced hepatotoxicity: metabolic, genetic and immunological basis," International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6990-7003, 2014
108. S.-H. Kim and D. J. Naisbitt, "Update on advances in research on idiosyncratic drug-induced liver injury," Allergy, Asthma and Immunology Research, vol. 8, no. 1, pp. 3-11, 2016
109. N. Greene, L. Fisk, R. T. Naven, R. R. Note, M. L. Patel, and D. J. Pelletier, "Developing structure-activity relationships for the prediction of hepatotoxicity," Chemical Research in Toxicology, vol. 23, no. 7, pp. 1215-1222, 2010
110. A. Suzuki, R. J. Andrade, E. Bjornsson et al. , "Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase-: unified list based on international collaborative work," Drug Safety, vol. 33, no. 6, pp. 503-522, 2010
111. C. J. Ursem,N. L. Kruhlak, J. F. Contrera, P. M. MacLaughlin, R. D. Benz, and E. J. Matthews, "Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities," Regulatory Toxicology and Pharmacology, vol. 54, no. 1, pp. 1-22, 2009
112. A. D. Rodgers, H. Zhu, D. Fourches, I. Rusyn, and A. Tropsha, "Modeling liver-related adverse effects of drugs using nearest neighbor quantitative structure-activity relationship method," Chemical Research in Toxicology, vol. 23, no. 4, pp. 724-732, 2010
113. X. Zhu and N. L. Kruhlak, "Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data," Toxicology, vol. 321, no. 1,pp. 62-72, 2014
114. M. Z. Sakatis, M. J. Reese, A. W. Harrell et al. , "Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds," Chemical Research in Toxicology, vol. 25, no. 10, pp. 2067-2082, 2012
115. Z. Weng, K. Wang, H. Li, and Q. Shi, "A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications," Oncotarget, vol. 6, no. 19, pp. 17031-17038, 2015
116. S.-H. Huang, C.-W. Tung, F. Fülöp, and J.-H. Li, "Developing a QSAR model for hepatotoxicity screening of the active compounds in traditional Chinese medicines," Food and Chemical Toxicology, vol. 78, pp. 71-77, 2015
117. F. Shah and N. Greene, "Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space," Chemical Research in Toxicology, vol. 27, no. 1, pp. 86-98, 2014
118. M. D. Aleo, Y. Luo, R. Swiss, P. D. Bonin, D. M. Potter, and Y. Will, "Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump," Hepatology, vol. 60, no. 3, pp. 1015-1022, 2014
119. H. Garside, K. F. Marcoe, J. Chesnut-Speelman et al. , "Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes," Toxicology in Vitro, vol. 28, no. 2, pp. 171-181, 2014
120. T. Tomida, H. Okamura, M. Satsukawa, T. Yokoi, and Y. Konno, "Multiparametric assay usingHepaRGcells for predicting druginduced liver injury," Toxicology Letters, vol. 236, no. 1, pp. 16-24, 2015
121. A. Hill, N. Mesens, M. Steemans, J. J. Xu, and M. D. Aleo, "Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development," Drug Metabolism Reviews, vol. 44, no. 1, pp. 127-140, 2012
122. D. Jennen, J. Polman, M. Bessem, M. Coonen, J. van Delft, and J. Kleinjans, "Drug-induced liver injury classificationmodel based on in vitro human transcriptomics and in vivo rat clinical chemistry data," Systems Biomedicine, vol. 2, no. 4, pp. 63-70, 2014
123. W. Mattes, K. Davis, E. Fabian et al. , "Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma," Toxicology Letters, vol. 230, no. 3, pp. 467-478, 2014
124. M. Zhang, M. Chen, and W. Tong, "Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans" Chemical Research in Toxicology, vol. 25, no. 1, pp. 122-129, 2012
125. Z. Lin and Y. Will, "Evaluation of drugs with specific organ toxicities in organ-specific cell lines," Toxicological Sciences, vol. 126, no. 1, pp. 114-127, 2012
126. S. Lu, S. Nadanaciva, R. Swiss, B. Jessen, and Y. Will, "Lysosomes, Compound Accumulation and in vitro Toxicity. Abstract number 1650," The Toxicologist: Supplement to Toxicological Sciences, 355, 2011
127. F. Shah, S. Louise-May, and N. Greene, "Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG2 cell lines," Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 12, pp. 2753-2757, 2014
128. J. A. Dykens, J. D. Jamieson, L. D. Marroquin et al. , "In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone," Toxicological Sciences, vol. 103, no. 2, pp. 335-345, 2008
129. S. Nadanaciva, J. A. Dykens, A. Bernal, R. A. Capaldi, and Y. Will, "Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration," Toxicology and Applied Pharmacology, vol. 223, no. 3, pp. 277-287, 2007
130. B. D. Cosgrove, B. M. King, M. A. Hasan et al. , "Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity," Toxicology and Applied Pharmacology, vol. 237, no. 3, pp. 317-330, 2009
131. J. G. Kenna, S. H. Stahl, J. A. Eakins et al. , "Multiple compoundrelated adverse properties contribute to liver injury caused by Endothelin receptor antagonists," Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 2, pp. 281-290, 2015
132. X. Chu, K. Korzekwa, R. Elsby et al. , "Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver," Clinical Pharmacology & Therapeutics, vol. 94, no. 1, pp. 126-141, 2013
133. M. J. Santostefano, V. M. Richardson, N. J. Walker et al. , "Dosedependent localization of TCDD in isolated centrilobular and periportal hepatocytes," Toxicological Sciences, vol. 52, no. 1, pp. 9-19, 1999
134. S. Hohenester, L. Maillette de Buy Wenniger, C. C. Paulusma et al. , "A biliary HCO? 3 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes," Hepatology, vol. 55, no. 1, pp. 173-183, 2012
135. P. Y. Muller and M. N. Milton, "The determination and interpretation of the therapeutic index in drug development," Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 751-761, 2012
136. M. Kessel, F. Gieseler, and B. G. Woodcock, "Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells," European Journal of Clinical Pharmacology, vol. 55, no. 5, pp. 369-373, 1999
137. J. J. Palmgrén, J. Mönkkönen, T. Korjamo, A. Hassinen, and S. Auriola, "Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions," European Journal of Pharmaceutics and Biopharmaceutics, vol. 64, no. 3, pp. 369-378, 2006
138. N. J. Hewitt, M. J. G. Lechón, J. B. Houston et al. , "Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies," Drug Metabolism Reviews, vol. 39, no. 1, pp. 159-234, 2007
139. J. C. Bouvy, M. A. Koopmanschap, R. R. Shah, and H. Schellekens, "The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies," Clinical Pharmacology and Therapeutics, vol. 91, no. 2, pp. 281-288, 2012
140. E. Park, J. Willard, D. Bi, M. Fiszman, D. Kozeli, and J. Koerner, "The impact of drug-related QT prolongation on FDA regulatory decisions," International Journal of Cardiology, vol. 168, no. 5, pp. 4975-4976, 2013
141. P. T. Sager, G. Gintant, J. R. Turner, S. Pettit, and N. Stockbridge, "Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium," American Heart Journal, vol. 167, no. 3, pp. 292-300, 2014
142. I. Cavero and H. Holzgrefe, "Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative,"ExpertOpinion onDrug Safety, vol. 13,no. 6, pp. 745-758, 2014
143. R. A. Star and R. S. Rasooly, "Searching for array standards in Rockville," Nature Biotechnology, vol. 19,no. 5, pp. 418-419, 2001
144. A. Brazma, P. Hingamp, J. Quackenbush et al. , "Minimuminformation about a microarray experiment (MIAME)-toward standards for microarray data," Nature Genetics, vol. 29, no. 4, pp. 365-371, 2001
145. A. Brazma, "Minimum information about a microarray experiment (MIAME)-successes, failures, challenges," TheScientific-WorldJournal, vol. 9, pp. 420-423, 2009
146. S. Rogers and A. Cambrosio, "Making a new technology work: the standardization and regulation of microarrays," Yale Journal of Biology and Medicine, vol. 80, no. 4, pp. 165-178, 2007
147. L. Shi, L. H. Reid, W. D. Jones et al. , "The MicroArray Quality Control (MAQC) project shows inter-and intraplatformreproducibility of gene expressionmeasurements," Nature Biotechnology, vol. 24, no. 9, pp. 1151-1161, 2006
148. Z. Gan, J. Wang, N. Salomonis et al. , "MAAMD: a workflow to standardize meta-analyses and comparison of affymetrix microarray data," BMC Bioinformatics, vol. 15, no. 1, article 69, 2014
149. L. Shi, R. G. Perkins, H. Fang, and W. Tong, "Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential," Current Opinion in Biotechnology, vol. 19, no. 1, pp. 10-18, 2008
150. D. Kirkland, S. Pfuhler, D. Tweats et al. , "How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAMWorkshop,"Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol. 628, no. 1, pp. 31-55, 2007
151. D. Kirkland, P. Kasper, L. Müller, R. Corvi, and G. Speit, "Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop," Mutation Research-Genetic Toxicology and Environmental Mutagenesis, vol. 653, no. 1-2, pp. 99-108, 2008
152. I. Kola and J. Landis, "Can the pharmaceutical industry reduce attrition rates" Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 711-715, 2004
153. J. Wang, L. Urban, and D. Bojanic, "Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety," Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 5, pp. 641-665, 2007
154. J. Hynes, S. Nadanaciva, R. Swiss, C. Carey, S. Kirwan, and Y. Will, "A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays," Toxicology in Vitro, vol. 27, no. 2, pp. 560-569, 2013
155. D. M. Dambach, B. A. Andrews, and F. Moulin, "New technologies and screening strategies for hepatotoxicity: use of in vitro models," Toxicologic Pathology, vol. 33, no. 1, pp. 17-26, 2005
156. H. Hosomi, S. Akai, K. Minami et al. , "An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and-glutamylcysteine synthetase knockdown cells," Toxicology in Vitro, vol. 24, no. 3, pp. 1032-1038, 2010
157. L. Tolosa, M. J. Gómez-Lechón, G. Pérez-Cataldo, J. V. Castell, and M. T. Donato, "HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved," Archives of Toxicology, vol. 87, no. 6, pp. 1115-1127, 2013
158. X.-W. Zhu, A. Sedykh, and S.-S. Liu, "Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information," Journal of Applied Toxicology, vol. 34, no. 3, pp. 281-288, 2014
159. J. Zhang, U. Doshi, A. Suzuki et al. , "Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: results from 152 marketed drugs with known liver injury profiles," Chemico-Biological Interactions, vol. 255, pp. 3-11, 2016
160. J. H. Ansede, W. R. Smith, C. H. Perry, R. L. St Claire III, and K. R. Brouwer, "An in vitro assay to assess transporterbased cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes," Drug Metabolism and Disposition, vol. 38, no. 2, pp. 276-280, 2010
161. K. K. Wolf,S. Vora, L. O. Webster,G. T. Generaux, J. W. Polli, and K. L. R. Brouwer, "Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport," Toxicology in Vitro, vol. 24, no. 1, pp. 297-309, 2010
162. J. A. Barber, S. H. Stahl, C. Summers et al. , "Quantification of drug-induced inhibition of canalicular cholyl-l-lysylfluorescein excretion from hepatocytes by high content cell imaging," Toxicological Sciences, vol. 148, no. 1,Article IDkfv159, pp. 48-59, 2015
163. A. Sharanek, A. Burban, L. Humbert et al. , "Cellular accumulation and toxic effects of bile acids in cyclosporine A-treated hepaRG hepatocytes," Toxicological Sciences, vol. 147, no. 2, Article ID kfv155, pp. 573-587, 2015
164. R. L. Sison-Young, V. M. Lauschke, E. Johann et al. , "A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity," Archives of Toxicology, 2016
165. M. Burbank, A. Sharanek,A. Burban, R. J. Weaver, C. Guguen-Guillouzo, and A. Guillouzo, "Selective bile canalicular changes induced by cholestatic drugs," Toxicology Letters, vol. 238, no. 2, supplement, p. S301, 2015
166. S. Dawson, S. Stahl, N. Paul, J. Barber, and J. G. Kenna, "In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans," Drug Metabolism and Disposition, vol. 40, no. 1, pp. 130-138, 2012
167. J. M. Pedersen, P. Matsson, C. A. S. Bergström et al. , "Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11)," Toxicological Sciences, vol. 136, no. 2, pp. 328-343, 2013
168. S. Nakayama, R. Atsumi, H. Takakusa et al. , "A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding," Drug Metabolism and Disposition, vol. 37, no. 9, pp. 1970-1977, 2009
169. T. Usui, M. Mise, T. Hashizume, M. Yabuki, and S. Komuro, "Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins," Drug Metabolismand Disposition, vol. 37, no. 12, pp. 2383-2392, 2009.